The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Chronic Obstructive Pulmonary Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.

Some of the key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Obstructive Pulmonary Disease treatment therapies with a considerable amount of success over the years. 

• Chronic Obstructive Pulmonary Disease companies working in the treatment market are Hoffmann-La Roche, Eurofarma Laboratorios S.A.,  Sunshine Guojian Pharmaceutical, Regend Therapeutics, GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, AstraZeneca, Nuance Pharma, Sanofi, University of Miami, Chiesi Farmaceutici S.p.A., Fundacio Privada Mon Clinic, Temple University, Merck Sharp & Dohme LLC, AstraZeneca, Northside Hospital, Inc., Incyte Corporation, SCM Lifescience Co., LTD., Dana-Farber Cancer Institute, Syndax Pharmaceuticals, and others, are developing therapies for the Chronic Obstructive Pulmonary Disease treatment 

• Emerging Chronic Obstructive Pulmonary Disease therapies in the different phases of clinical trials are- Astegolimab, Fluticasone 250mcg, 611 300 mg, REGEND001, FF/UMEC/VI, TQC3721, HRG2005 inhalation, Benralizumab, Ensifentrine, Itepekimab SAR440340, Bevespi, CHF6001 1600µg, Trelegy Ellipta 100, Mepolizumab, Quercetin, MK-5475, Mitiperstat (AZD4831), Belumosudil, Axatilimab, INCA034176, SCM-CGH, Fluticasone, SNDX-6352, and others are expected to have a significant impact on the Chronic Obstructive Pulmonary Disease market in the coming years.   

• In January 2024, Theravance Biopharma, Inc. (NASDAQ: TBPH) has released findings from the Phase 4 PIFR-2 trial of YUPELRI® (revefenacin) inhalation solution, the sole once-daily, nebulized long-acting muscarinic antagonist (LAMA) authorized in the U.S. for COPD maintenance therapy. The PIFR-2 study aimed to illustrate superior lung function enhancement with YUPELRI administered via standard jet nebulizer versus Spiriva® (tiotropium) delivered through a dry powder inhaler (Spiriva® HandiHaler®) in severe to very severe COPD patients with suboptimal peak inspiratory flow rate (PIFR).

• In April 2023, The Phase III trial testing ensifentrine as a maintenance therapy for chronic obstructive pulmonary disease (COPD) was dosed with the first patient, according to a press release from the UK-based Verona Pharma and its partner Nuance Pharma.

• According to a 12-month Phase 3 clinical trial published in the New England Journal of Medicine, patients with type 2 inflammation of chronic obstructive pulmonary disease experienced quick and long-lasting improvements in their condition.

• The disease known as chronic obstructive pulmonary disease (COPD) is widespread, treatable, and preventive. The persistent and progressive airflow restriction that characterises this poorly reversible lung illness is brought on by an exacerbated chronic inflammatory response in the airways and the lungs as a result of irritating particles or gases.

Chronic Obstructive Pulmonary Disease Overview

The disease known as chronic obstructive pulmonary disease (COPD) is widespread, treatable, and preventive. The persistent and progressive airflow restriction that characterises this poorly reversible lung illness is brought on by an exacerbated chronic inflammatory response in the airways and the lungs as a result of irritating particles or gases.

Get a Free Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

Emerging Chronic Obstructive Pulmonary Disease Drugs Under Different Phases of Clinical Development Include:

• Astegolimab: Hoffmann-La Roche

• Fluticasone 250mcg: Eurofarma Laboratorios S.A.

• 611 300 mg: Sunshine Guojian Pharmaceutical

• REGEND001: Regend Therapeutics

• FF/UMEC/VI: GlaxoSmithKline

• TQC3721: Chia Tai Tianqing Pharmaceutical

• HRG2005 inhalation: Jiangsu HengRui Medicine

• Benralizumab: AstraZeneca

• Ensifentrine: Nuance Pharma

• Itepekimab SAR440340: Sanofi

• Bevespi: University of Miami

• CHF6001 1600µg: Chiesi Farmaceutici S.p.A.

• Trelegy Ellipta 100: Fundacio Privada Mon Clinic

• Mepolizumab: GlaxoSmithKline

• Quercetin: Temple University

• MK-5475: Merck Sharp & Dohme LLC

• Mitiperstat (AZD4831): AstraZeneca

• Belumosudil: Northside Hospital, Inc.

• Axatilimab: Incyte Corporation

• INCA034176: Incyte Biosciences Japan GK

• SCM-CGH: SCM Lifescience Co., LTD.

• Fluticasone: Dana-Farber Cancer Institute

• SNDX-6352: Syndax Pharmaceuticals

Chronic Obstructive Pulmonary Disease Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Intravenous

• Subcutaneous

• Intramuscular

Chronic Obstructive Pulmonary Disease Molecule Type

Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment

• Chronic Obstructive Pulmonary Disease Assessment by Product Type

• Chronic Obstructive Pulmonary Disease By Stage and Product Type

• Chronic Obstructive Pulmonary Disease Assessment by Route of Administration

• Chronic Obstructive Pulmonary Disease By Stage and Route of Administration

• Chronic Obstructive Pulmonary Disease Assessment by Molecule Type

• Chronic Obstructive Pulmonary Disease by Stage and Molecule Type

DelveInsight’s Chronic Obstructive Pulmonary Disease Report covers around 70+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Obstructive Pulmonary Disease product details are provided in the report. Download the Chronic Obstructive Pulmonary Disease pipeline report to learn more about the emerging Chronic Obstructive Pulmonary Disease therapies

Some of the key companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include:

Key companies developing therapies for Chronic Obstructive Pulmonary Disease are – Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceuticals, Astellas Pharma, AstraZeneca, Boehringer-Ingelheim, Brickell Biotech, Chiesi Farmaceutici S.p.A., Chiesi USA, Inc., Dimerix, EpiEndo Pharmaceuticals, Genentech, GlaxoSmithkline, GSNOR Therapeutics, InMed Pharmaceuticals, Ionis Pharmaceuticals, KeyMed Biosciences, Laboratoires SMB, Mereo BioPharma, Meridigen Biotech, Nephron Pharmaceuticals, Novartis, Pulmatrix Inc., Pulmotect, Quercegen Pharmaceuticals, Regend Therapeutics, Regeneron Pharmaceuticals/Sanofi, Sulfateq BV, Synairgen, Tetherex Pharmaceuticals, Verona Pharma, Vertex Pharmaceuticals, and several others.

Chronic Obstructive Pulmonary Disease Pipeline Analysis:

The Chronic Obstructive Pulmonary Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.

• Chronic Obstructive Pulmonary Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease drugs and therapies

Chronic Obstructive Pulmonary Disease Pipeline Market Drivers

• Rising disease burden associated with COPD, increasing focus on therapy development, favorable insurance coverage for COPD treatment are some of the important factors that are fueling the Chronic Obstructive Pulmonary Disease Market.

Chronic Obstructive Pulmonary Disease Pipeline Market Barriers

• However, concerns regarding the long term use of current ICS/LABA inhalers, poor regimen adherence by patients, treatment costs and other factors are creating obstacles in the Chronic Obstructive Pulmonary Disease Market growth.

Scope of Chronic Obstructive Pulmonary Disease Pipeline Drug Insight    

• Coverage: Global

• Key Chronic Obstructive Pulmonary Disease Companies: Hoffmann-La Roche, Eurofarma Laboratorios S.A.,  Sunshine Guojian Pharmaceutical, Regend Therapeutics, GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, AstraZeneca, Nuance Pharma, Sanofi, University of Miami, Chiesi Farmaceutici S.p.A., Fundacio Privada Mon Clinic, Temple University, Merck Sharp & Dohme LLC, AstraZeneca, Northside Hospital, Inc., Incyte Corporation, SCM Lifescience Co., LTD., Dana-Farber Cancer Institute, Syndax Pharmaceuticals, and others

• Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab, Fluticasone 250mcg, 611 300 mg, REGEND001, FF/UMEC/VI, TQC3721, HRG2005 inhalation, Benralizumab, Ensifentrine, Itepekimab SAR440340, Bevespi, CHF6001 1600µg, Trelegy Ellipta 100, Mepolizumab, Quercetin, MK-5475, Mitiperstat (AZD4831), Belumosudil, Axatilimab, INCA034176, SCM-CGH, Fluticasone, SNDX-6352, and others

• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies

• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers 

Request for Sample PDF Report for Chronic Obstructive Pulmonary Disease Pipeline Assessment and clinical trials

Table of Contents 

1. Chronic Obstructive Pulmonary Disease Report Introduction

2. Chronic Obstructive Pulmonary Disease Executive Summary

3. Chronic Obstructive Pulmonary Disease Overview

4. Chronic Obstructive Pulmonary Disease- Analytical Perspective In-depth Commercial Assessment

5. Chronic Obstructive Pulmonary Disease Pipeline Therapeutics

6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase II/III)

7. Chronic Obstructive Pulmonary Disease Mid Stage Products (Phase II)

8. Chronic Obstructive Pulmonary Disease Early Stage Products (Phase I)

9. Chronic Obstructive Pulmonary Disease Preclinical Stage Products

10. Chronic Obstructive Pulmonary Disease Therapeutics Assessment

11. Chronic Obstructive Pulmonary Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Obstructive Pulmonary Disease Key Companies

14. Chronic Obstructive Pulmonary Disease Key Products

15. Chronic Obstructive Pulmonary Disease Unmet Needs

16 . Chronic Obstructive Pulmonary Disease Market Drivers and Barriers

17. Chronic Obstructive Pulmonary Disease Future Perspectives and Conclusion

18. Chronic Obstructive Pulmonary Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/